Seeking Alpha

Sapacitabine active against ovarian cancer, Cyclacel soars

  • Cyclacel Pharmaceuticals (CYCC) soars 35% before the bell.
  • A poster presentation from AACR shows the active metabolite of sapacitabine was active against three quarters of isolated primary ovarian cancer samples.
  • By contrast, the chemotherapy drug cisplatin was active in "less than half" of the samples.
  • More than half of the platinum-resistant samples were sensitive to sapacitabine. (PR)
  • Janney initiated the shares at Buy earlier this month.
  • For more, see a recent article by SA contributor Scrying Biotech who said on September 7 that "with or without you, Cyclacel is going to rise."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|